Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020-2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality.

Autor: Kandeel A; Preventive Sector, Ministry of Health and Population, Cairo, Egypt., Moatasim Y; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Fahim M; Department of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt., Bahaaeldin H; Department of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt. halaaabahaa@gmail.com., El-Shesheny R; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Roshdy WH; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Kamel MN; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Shawky S; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Gomaa M; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Naguib A; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Guindy NE; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Deghedy O; Department of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt., Kamel R; Department of Epidemiology and Surveillance, Preventive Sector, Ministry of Health and Population, Cairo, Egypt., Khalifa M; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Galal R; Public Health Initiatives, Cairo, 11613, Egypt., Hassany M; National Hepatology and Tropical Medicine Research Institute, Ministry of Health and Population, Cairo, 11613, Egypt., Mahmoud G; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt., Kandeil A; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Afifi S; Ministry of Health and Population Consultant, Cairo, Egypt., Mohsen A; Community Medicine Department, National Research Centre, Cairo, Egypt., Fattah MA; Preventive Sector, Central Administration for Preventive Affairs, Ministry of Health and Population, Cairo, Egypt., Kayali G; Human Link, Dubai, United Arab Emirates., Ali MA; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza, 12622, Egypt., Abdelghaffar K; Minister of Health and Population, Cairo, Egypt.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2023 Aug 18; Vol. 23 (1), pp. 542. Date of Electronic Publication: 2023 Aug 18.
DOI: 10.1186/s12879-023-08527-y
Abstrakt: Background: The o severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has killed millions of people and caused widespread concern around the world. Multiple genetic variants of SARS-CoV-2 have been identified as the pandemic continues. Concerns have been raised about high transmissibility and lower vaccine efficacy against omicron. There is an urgent need to better describe how omicron will impact clinical presentation and vaccine efficacy. This study aims at comparing the epidemiologic, clinical, and genomic characteristics of the omicron variant prevalent during the fifth wave with those of other VOCs between May 2020 and April 2022.
Methods: Epidemiological data were obtained from the National Electronic Diseases Surveillance System. Secondary data analysis was performed on all confirmed COVID-19 patients. Descriptive data analysis was performed for demographics and patient outcome and the incidence of COVID-19 was calculated as the proportion of SARS-CoV-2 confirmed patients out of the total population of Egypt. Incidence and characteristics of the omicron cohort from January- April 2022, were compared to those confirmed from May 2020-December 2021. We performed the whole-genome sequencing of SARS-CoV-2 on 1590 specimens using Illumina sequencing to describe the circulation of the virus lineages in Egypt.
Results: A total of 502,629 patients enrolled, including 60,665 (12.1%) reported in the fifth wave. The incidence rate of omicron was significantly lower than the mean of incidences in the previous subperiod (60.1 vs. 86.3/100,000 population, p < 0.001). Symptoms were reported less often in the omicron cohort than in patients with other variants, with omicron having a lower hospitalization rate and overall case fatality rate as well. The omicron cohort tended to stay fewer days at the hospital than did those with other variants. We analyzed sequences of 2433 (1590 in this study and 843 were obtained from GISAID platform) Egyptian SARS-CoV-2 full genomes. The first wave that occurred before the emergence of global variants of concern belonged to the B.1 clade. The second and third waves were associated with C.36. Waves 4 and 5 included B.1.617.2 and BA.1 clades, respectively.
Conclusions: The study indicated that Omicron-infected patients had milder symptoms and were less likely to be hospitalized; however, patients hospitalized with omicron had a more severe course and higher fatality rates than those hospitalized with other variants. Our findings demonstrate the importance of combining epidemiological data and genomic analysis to generate actionable information for public health decision-making.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje